FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of organic chemistry and pharmaceutics and deals with novel anti-hypertension salt of general formula [(R1-COO-)·(H3N-R2)], where R1 is inhibitor of angiotensin-converting enzyme, selected from group, which consists of perindoprilat, ramiprilat, spiraprilat, benazeprilat, moexiprilat, trandalaprilat, fosinoprilat, enalaprilat, zofenoprilat or lisinopril, and R2 -calcium channel blocker, selected from group, consisting of amlodipine, lacidipine, felodipine, isradipine.
EFFECT: invention ensures reduction of therapeutic doses and side effects.
3 dwg, 2 tbl, 3 ex
Authors
Dates
2011-03-10—Published
2009-05-14—Filed